The Trump administration’s recent move to advance federal cannabis rescheduling has elicited varied reactions from bipartisan U.S. senators, as detailed in interviews with Marijuana Moment. While some Democrats argue the reform does not go far enough, certain Republicans have expressed concerns regarding the process, even as one GOP lawmaker indicated a softening stance on medical cannabis due to personal observations.
Senatorial Perspectives on Federal Cannabis Rescheduling
The Department of Justice announced that marijuana products regulated by a state medical cannabis license, alongside any products approved by the Food and Drug Administration (FDA), would immediately transition to Schedule III of the Controlled Substances Act. An administrative hearing is scheduled for summer to consider broader cannabis rescheduling, including for recreational products.
Republican Concerns and Evolving Views
- Senator Ted Budd (R-NC) stated he is “no fan” of the rescheduling action, emphasizing that medical products require “standard research” which he believes has been partially bypassed. However, he acknowledged the move “owning up to the fact that it is not the same as heroin and cocaine,” while still calling for full research into potential issues.
- Senator Lisa Murkowski (R-AK) questioned the practical implementation of a bifurcated scheduling approach, asking how honesty regarding recreational versus medical use would be verified.
- Senator Cynthia Lummis (R-WY), while noting that marijuana reform is “not my cup of tea,” indicated a shift in her position. She cited friends who use medical marijuana for conditions like multiple sclerosis, explaining that specialized advice and treatment from “credible medical marijuana-only facilities” provide them relief. This has led her personal feelings about medical cannabis to “soften a little bit,” acknowledging the increasing sophistication of the medical marijuana industry.
Democratic Calls for Broader Reform
- Senator John Hickenlooper (D-CO) expressed that the move to Schedule III “doesn’t go far enough,” advocating for cannabis to be treated akin to alcohol. He suggested the current approach “muddies the water” by attempting to satisfy multiple constituencies without committing to a comprehensive reform. Senator Hickenlooper also noted that while cannabis has some downsides, similar to alcohol, it does not appear to contribute to violence.
- Senator Ron Wyden (D-OR) criticised the long-standing use of cannabis as a “political football” and described the selective approach, differentiating medical and recreational cannabis under federal law, as “bad for the country.” He called for “justice and fairness” in reform efforts.
- Representative Alexandria Ocasio-Cortez (D-NY), from the House, supported the Trump administration’s rescheduling move, though she noted it “doesn’t quite make all the wrongs right” for those affected by past drug policies.
Congressional Actions and Policy Implications
The discussion surrounding federal cannabis rescheduling is not limited to the Senate. As previously reported by Hemp Gazette, a House appropriations subcommittee recently voted to block federal officials from taking further steps to carry out cannabis rescheduling, indicating ongoing legislative friction. This congressional opposition highlights the complex political landscape surrounding cannabis policy in the United States, building on earlier coverage of similar legislative efforts.
The Department of Justice’s framework for moving certain cannabis products to Schedule III marks a significant administrative adjustment. However, the diverse reactions from lawmakers underscore the continuing debate over the appropriate federal classification and regulation of cannabis, particularly concerning the distinction between medical and recreational applications and the need for robust scientific research.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
